Aviron Message Board - Msg: 5660341

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Aviron

AVIR 3.260

+0.3%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: mauser96 who wrote (354)	9/3/1998 1:50:00 AM
From: Mel Kaplan	Read Replies (1) of 645

Lucius, You may be aware that the plan for the nasal instillation is to use live attenuated virus vaccine for the children population and heat-killed virus vaccine for aged populations, Presumably, this represents a concern for the higher incidence of relatively immunodeficient individuals among the elderly, and the risk of clinical infection using live virus, even if attenuated, in this population. In the original article in the NEJM, it was reported that in a few children, a transient fever occurred in the week after nasal instillation. This was considered inconsequential though unexplained. All of the above is to emphasize the importance of careful quality control of the vaccine mixtures used and of clinical monitoring for reactions or infection. As you point out, children may exhibit immunodeficient states on a genetic or physiologic basis. Appreciated your note. Mel

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next